Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference
PHOTO
Supplies of Pfizer's Paxlovid in China are still unable to meet demand but local production of the anti-viral COVID drug should be able to start soon, a Chinese health expert said on Wednesday.
Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference. (Reporting by Yew Lun Tian; Writing by Brenda Goh; Editing by Jacqueline Wong)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
